Actinium Pharmaceuticals, Inc. – ‘10-K’ for 12/31/18 – ‘EX-101.CAL’

On:  Friday, 3/15/19, at 5:02pm ET   ·   For:  12/31/18   ·   Accession #:  1213900-19-4269   ·   File #:  1-36374

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    706K 
 2: EX-3.7      Certificate of Amendment to Actinium's Certificate  HTML     17K 
                of Incorporation                                                 
 3: EX-10.37    Consulting Agreement, Dated December 21, 2018,      HTML     63K 
                Between Actinium Pharmaceuticals, Inc. and Nitya                 
                Ray                                                              
 4: EX-10.38    Amended and Restated at Market Issuance Sales       HTML    237K 
                Agreement, Dated December 28, 2018, by and Among                 
                Actinium Pharmaceuticals, Inc. and B. Riley Fbr,                 
                Inc. and Jonestrading Institutional Services LLC                 
 5: EX-10.39    Seventh Amendment to the 2013 Amended and Restated  HTML     21K 
                Stock Plan, as Amended                                           
 6: EX-23.1     Consent of Gbh CPAs, Pc.                            HTML     18K 
 7: EX-23.2     Consent of Marcum LLP.                              HTML     18K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
18: R1          Document and Entity Information                     HTML     56K 
19: R2          Consolidated Balance Sheets                         HTML     88K 
20: R3          Consolidated Balance Sheets (Parenthetical)         HTML     41K 
21: R4          Consolidated Statements of Operations               HTML     52K 
22: R5          Consolidated Statement of Changes in Stockholders'  HTML     72K 
                Equity                                                           
23: R6          Consolidated Statements of Cash Flows               HTML     93K 
24: R7          Description of Business and Summary of Significant  HTML     60K 
                Accounting Policies                                              
25: R8          Derivative Liabilities                              HTML     34K 
26: R9          Prepaid Expenses and Other Current Assets           HTML     24K 
27: R10         Property and Equipment                              HTML     30K 
28: R11         Commitments and Contingencies                       HTML     35K 
29: R12         Equity                                              HTML     79K 
30: R13         Income Taxes                                        HTML     43K 
31: R14         Subsequent Event                                    HTML     24K 
32: R15         Description of Business and Summary of Significant  HTML    105K 
                Accounting Policies (Policies)                                   
33: R16         Description of Business and Summary of Significant  HTML     36K 
                Accounting Policies (Tables)                                     
34: R17         Derivative Liabilities (Tables)                     HTML     34K 
35: R18         Prepaid Expenses and Other Current Assets (Tables)  HTML     24K 
36: R19         Property and Equipment (Tables)                     HTML     29K 
37: R20         Commitments and Contingencies (Tables)              HTML     23K 
38: R21         Equity (Tables)                                     HTML     48K 
39: R22         Income Taxes (Tables)                               HTML     40K 
40: R23         Description of Business and Summary of Significant  HTML     27K 
                Accounting Policies (Details)                                    
41: R24         Description of Business and Summary of Significant  HTML     23K 
                Accounting Policies (Details 1)                                  
42: R25         Description of Business and Summary of Significant  HTML     33K 
                Accounting Policies (Details 2)                                  
43: R26         Description of Business and Summary of Significant  HTML     53K 
                Accounting Policies (Details Textual)                            
44: R27         Derivative Liabilities (Details)                    HTML     25K 
45: R28         Derivative Liabilities (Details 1)                  HTML     40K 
46: R29         Derivative Liabilities (Details Textual)            HTML     33K 
47: R30         Prepaid Expenses and Other Current Assets           HTML     30K 
                (Details)                                                        
48: R31         Prepaid Expenses and Other Current Assets (Details  HTML     21K 
                Textual)                                                         
49: R32         Property and Equipment (Details)                    HTML     39K 
50: R33         Property and Equipment (Details 1)                  HTML     24K 
51: R34         Property and Equipment (Details Textual)            HTML     23K 
52: R35         Commitments and Contingencies (Details)             HTML     33K 
53: R36         Commitments and Contingencies (Details Textual)     HTML     68K 
54: R37         Equity (Details)                                    HTML     66K 
55: R38         Equity (Details 1)                                  HTML     69K 
56: R39         Equity (Details Textual)                            HTML    360K 
57: R40         Income Taxes (Details)                              HTML     35K 
58: R41         Income Taxes (Details 1)                            HTML     75K 
59: R42         Income Taxes (Details Textual)                      HTML     42K 
60: R43         Subsequent Event (Details)                          HTML     47K 
62: XML         IDEA XML File -- Filing Summary                      XML    102K 
61: EXCEL       IDEA Workbook of Financial Reports                  XLSX     60K 
12: EX-101.INS  XBRL Instance -- atnm-20181231                       XML   1.01M 
14: EX-101.CAL  XBRL Calculations -- atnm-20181231_cal               XML    103K 
15: EX-101.DEF  XBRL Definitions -- atnm-20181231_def                XML    479K 
16: EX-101.LAB  XBRL Labels -- atnm-20181231_lab                     XML    835K 
17: EX-101.PRE  XBRL Presentations -- atnm-20181231_pre              XML    674K 
13: EX-101.SCH  XBRL Schema -- atnm-20181231                         XSD    134K 
63: ZIP         XBRL Zipped Folder -- 0001213900-19-004269-xbrl      Zip    107K 

‘EX-101.CAL’   —   XBRL Calculations — atnm-20181231_cal

This Exhibit is an XBRL XML File.

21 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/24  Actinium Pharmaceuticals, Inc.    10-Q        3/31/24   49:10M                                    EdgarAgents LLC/FA
 3/29/24  Actinium Pharmaceuticals, Inc.    S-8         3/29/24    4:57K                                    EdgarAgents LLC/FA
 3/29/24  Actinium Pharmaceuticals, Inc.    10-K       12/31/23   65:17M                                    EdgarAgents LLC/FA
 2/02/24  Actinium Pharmaceuticals, Inc.    S-3/A                  3:589K                                   EdgarAgents LLC/FA
11/02/23  Actinium Pharmaceuticals, Inc.    10-Q        9/30/23   46:4.2M                                   EdgarAgents LLC/FA
 8/14/23  Actinium Pharmaceuticals, Inc.    10-Q        6/30/23   45:4M                                     EdgarAgents LLC/FA
 8/11/23  Actinium Pharmaceuticals, Inc.    S-3                    4:540K                                   EdgarAgents LLC/FA
 5/15/23  Actinium Pharmaceuticals, Inc.    10-Q        3/31/23   47:5.9M                                   EdgarAgents LLC/FA
 3/31/23  Actinium Pharmaceuticals, Inc.    10-K       12/31/22   60:8.1M                                   EdgarAgents LLC/FA
11/14/22  Actinium Pharmaceuticals, Inc.    10-Q        9/30/22   47:3.4M                                   EdgarAgents LLC/FA
 8/19/22  Actinium Pharmaceuticals, Inc.    S-8         8/19/22    5:185K                                   EdgarAgents LLC/FA
 8/12/22  Actinium Pharmaceuticals, Inc.    10-Q        6/30/22   48:3.7M                                   EdgarAgents LLC/FA
 5/13/22  Actinium Pharmaceuticals, Inc.    10-Q        3/31/22   44:2.7M                                   EdgarAgents LLC/FA
 3/25/22  Actinium Pharmaceuticals, Inc.    10-K       12/31/21   56:4.2M                                   EdgarAgents LLC/FA
11/12/21  Actinium Pharmaceuticals, Inc.    10-Q        9/30/21   42:3.1M                                   EdgarAgents LLC/FA
 7/30/21  Actinium Pharmaceuticals, Inc.    10-Q        6/30/21   44:3.2M                                   EdgarAgents LLC/FA
 5/14/21  Actinium Pharmaceuticals, Inc.    10-Q        3/31/21   43:2.3M                                   EdgarAgents LLC/FA
 3/31/21  Actinium Pharmaceuticals, Inc.    10-K       12/31/20   56:3.5M                                   EdgarAgents LLC/FA
10/23/20  Actinium Pharmaceuticals, Inc.    10-Q        9/30/20   41:2.6M                                   EdgarAgents LLC/FA
 8/14/20  Actinium Pharmaceuticals, Inc.    10-Q        6/30/20   44:2.8M                                   EdgarAgents LLC/FA
 8/07/20  Actinium Pharmaceuticals, Inc.    S-3                    4:702K                                   EdgarAgents LLC/FA